The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
Abstract
Bisphosphonate drugs inhibit osteoclastic bone resorption and are widely used to treat skeletal complications in patients with tumor-induced osteolysis. We now show that zoledronic acid, a new generation bisphosphonate with a heterocyclic imidazole substituent, is also a potent inhibitor of angiogenesis. In vitro, zoledronic acid inhibits proliferation of human endothelial cells stimulated with fetal calf serum, basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (IC(50) values 4.1, 4.2, and 6.9 microM, respectively), and modulates endothelial cell adhesion and migration. In cultured aortic rings and in the chicken egg chorioallantoic membrane assay, zoledronic acid reduces vessel sprouting. When administered systemically to mice, zoledronic acid potently inhibits the angiogenesis induced by subcutaneous implants impregnated with bFGF [ED(50), 3 microg/kg (7.5 nmol/kg) s.c.]. These findings indicate that zoledronic acid has marked antiangiogenic properties that could augment its efficacy in the treatment of malignant bone disease and extend its potential clinical use to other diseases with an angiogenic component.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“these agents have also been shown to suppress the proliferation, adhesion, migration, and survival of endothelial cells in vitro (147, 148) while inducing endothelial cell apoptosis in vivo (149).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [147]
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Asahara, T., Masuda, H., Takahashi, T., Kalka, C., Pastore, C., Silver, M., Kearne, M., Magner, M., & Isner, J. M. (1999) · Circulation Research · doi:10.1161/01.res.85.3.221 · Cited by 3,263
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Bisphosphonates: Mechanisms of Action
Fleisch, H. A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,109
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D., Mundy, G. R., & Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,039
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 844
Self-citationReduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I., Solomayer, E., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D. R., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Montesano, R., Orci, L., & VASSALLI, P. (1983) · The Journal of Cell Biology · doi:10.1083/jcb.97.5.1648 · Cited by 647
Berenson, J. R., Lichtenstein, A. K., Porter, L., Dimopoulos, M. A., Bordoni, R. E., George, S., Lipton, A., Keller, A. M., Ballester, O., Kovacs, M. J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 645
Flagged first, then by citations
1 of the 33 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Boissier, 2020, Zoledronic acid inhibits in vivo experimental angiogenesis (abstract B3)., Bone, 30, 38S
- Bonjean, 2002, Zoledronic acid inhibits human endothelial cell adhesion to vitronectin and selectively alters the expression of extracellular matrix cell surface receptors (abstract B4)., Bone, 30, 38S
Cited by
Sorted by citations
Items 501–600 of 845
Management of the Patient Undergoing Radiotherapy or Chemotherapy
Ellis, E. (2013) · Elsevier eBooks · doi:10.1016/b978-0-323-09177-0.00019-0 · Cited by 11
Research Status of Systemic Adjuvant Therapy for Early Breast Cancer
Hu, W., Xu, D., & Li, N. (2023) · Cancer Control · doi:10.1177/10732748231209193 · Cited by 11
Osteonecrosis of the Jaw Beyond Bisphosphonates: Are There Any Unknown Local Risk Factors?
Lechner, J., von Baehr, V., & Zimmermann, B. (2021) · Clinical Cosmetic and Investigational Dentistry · doi:10.2147/ccide.s288603 · Cited by 11
Jamil, M. O., Jerome, M. S., Miley, D., Selander, K. S., & Robert, F. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s135802 · Cited by 11
Singh, S., Kidane, J., Wentworth, K. L., Motamedi, D., Morshed, S., Schober, A. E., & Hsiao, E. C. (2020) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-020-03240-2 · Cited by 11
Avascular Osteonecrosis of the Jaw as a Side Effect of Bisphosphonate Treatment
Bamias, A., Terpos, E., & Dimopoulos, M. A. (2010) · Onkologie · doi:10.1159/000313684 · Cited by 11
Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
Aft, R. (2011) · PubMed · Cited by 11
Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease
Wong, P. K. K., Borromeo, G. L., & Wark, J. D. (2013) · Rheumatology International · doi:10.1007/s00296-013-2771-7 · Cited by 10
The Duration and Safety of Osteoporosis Treatment
Abrahamsen, B., & Silverman, S. L. (2015) · Springer eBooks · doi:10.1007/978-3-319-23639-1 · Cited by 10
Screening for Anti-angiogenic Activity in Shiitake Mushroom (Lentinus edodes Berk) Extracts
Deocaris, C. C., Castro, M. C. P. D., Oabel, A. T., Co, E. L., & Mojica, E. E. (2004) · Journal of Medical Sciences(Faisalabad) · doi:10.3923/jms.2005.43.46 · Cited by 10
Could local delivery of bisphosphonates be a new therapeutic choice for hemangiomas?
Yu, H., & Qin, A. J. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.06.015 · Cited by 10
Teriparatide for the Treatment of Medication-Related Osteonecrosis of the Jaw
Chopra, K., & Malhan, N. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001182 · Cited by 10
Otto, M., Lux, C., Schlittenbauer, T., Halling, F., & Ziebart, T. (2021) · Oral and Maxillofacial Surgery · doi:10.1007/s10006-021-00982-8 · Cited by 10
A prospective randomized controlled clinical trial of zoledronic acid for bone metastases
Mystakidou, K., Katsouda, E., Parpa, E., Kouskouni, E. E., Chondros, C., Tsiatas, M. L., Galanos, A., & Vlahos, L. J. (2006) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/104990910602300107 · Cited by 10
Bisphosphonate-Related Osteonecrosis of the Mandible and Maxilla
Gill, S., Valencia, M. P., Sabino, M. L. C., Heideman, G. M., & Michel, M. A. (2009) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0b013e318186b179 · Cited by 10
Review: Epidemiology and Pathophysiology of Atypical Femur Fractures
Ng, A. C., Png, M. A., Chua, D. T. C., Koh, J. S. B., & Howe, T. S. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0198-z · Cited by 10
Biomaterial Thin Films by Soft Pulsed Laser Technologies for Biomedical Applications
Mihailescu, I. N., Bigi, A., György, E., Ristoscu, C., Sima, F., & Öner, E. T. (2014) · Springer series in materials science · doi:10.1007/978-3-319-02898-9_11 · Cited by 10
Zhao, D., Wu, J., Zhao, Y., Shao, W., Cheng, Q., Shao, X., Yuan, X., Ye, J., Gao, J., Jin, M., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1131-4 · Cited by 10
Hardouin, J., Guénin, E., Monteil, M., Caron, M., & Lecouvey, M. (2008) · Journal of Mass Spectrometry · doi:10.1002/jms.1379 · Cited by 10
Role of bisphosphonates in prostate cancer bone metastases
Guise, T. A. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00347-6 · Cited by 10
Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells
Carbonare, L. D., Valenti, M. T., Azzarello, G., Balducci, E., Crepaldi, G., Realdi, G., Vinante, O., & Giannini, S. (2005) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.03.018 · Cited by 10
Efficacy of zoledronate against neuroblastoma
Dickson, P. V., Hamner, J. B., Cauthen, L. A., Ng, C. Y., McCarville, M. B., & Davidoff, A. M. (2006) · Surgery · doi:10.1016/j.surg.2006.02.004 · Cited by 10
Bisphosphonates in early multiple myeloma
Sezer, O., Jakob, C., Zavrski, I., Heider, U., Fleissner, C., & Freund, M. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.00116.x · Cited by 10
Bisphosphonate-associated osteonecrosis of the jaws
Goss, A. N. (2007) · Climacteric · doi:10.1080/13697130601176726 · Cited by 10
Evolution of atypical femur fractures and the association with bisphosphonates.
Takemoto, R. C., McLaurin, T. M., Tejwani, N. C., & Egol, K. A. (2014) · PubMed · Cited by 9
Bojtor, B., Balla, B., Vaszilkó, M., Szentpéteri, S., Putz, Z., Kosa, J. P., & Lakatos, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910488 · Cited by 12
Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors
Brufsky, A. (2008) · Current Oncology Reports · doi:10.1007/s11912-008-0005-z · Cited by 9
Effect of alendronate on bone remodeling around implant in the rat
Park, R., Kim, J., Choi, H., Park, Y., Jung, H.-S., & Moon, H. (2013) · The Journal of Advanced Prosthodontics · doi:10.4047/jap.2013.5.4.374 · Cited by 9
Milstein, D. M. J., Lindeboom, J. A. H., & İnce, C. (2010) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2010.11.015 · Cited by 9
Decreased risk of breast cancer associated with oral bisphosphonate therapy
Mathew, A., & Mathew, A. (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s16356 · Cited by 9
Tohashi, K., Nakabayashi, M., Kodani, I., Kidani, K., & Ryoke, K. (2016) · PubMed Central · Cited by 9
Zafar, S., Cullinan, M. P., Drummond, B. K., Seymour, G. J., & Coates, D. E. (2020) · Journal of Oral Science · doi:10.2334/josnusd.19-0130 · Cited by 9
Efeito Anti-Tumoral dos Bisfosfonatos: uma Nova Perspectiva Terapêutica
Vasconcellos, D. V., Duarte, M. E. L., & Maia, R. C. (2004) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2004v50n1.2058 · Cited by 9
Infection, vascularization, remodelling - are stem cells the answers for bone diseases of the jaws?
Handschel, J. G., & Meyer, U. (2011) · Head & Face Medicine · doi:10.1186/1746-160x-7-5 · Cited by 9
Didden, K., SMET, L. D., Vandenberghe, L., Sciot, R., & Degreef, I. (2012) · Chirurgie de la Main · doi:10.1016/j.main.2012.10.168 · Cited by 8
Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid
Marra, M., Santini, D., Tonini, G., Meo, G., Zappavigna, S., Facchini, G., Morabito, A., Abbruzzese, A., Cartenì, G., Budillon, A., et al. (2008) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2008.06.023 · Cited by 8
Leonida, A., Vescovi, P., Baldoni, M., Rossi, G., & Lauritano, D. (2010) · Journal of Oral Implantology · doi:10.1563/aaid-joi-d-09-00132.1 · Cited by 8
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates.
Pavkovic, M., Petrushevska, G., Jovanović, R., Каранфилски, О., Cevreska, L. A., Stankovic, S., & Stojanovic, A. (2010) · PubMed · Cited by 8
CD34 and CD105 Microvessels in Resected Bone Specimen May Implicate Wound Healing in MRONJ
Marcianò, A., Ieni, A., Mauceri, R., & Oteri, G. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111362 · Cited by 8
Bellone, F., Catalano, A., Sottile, A. R., Gaudio, A., Loddo, S., Corica, F., & Morabito, N. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.748438 · Cited by 8
Odontogenic Bacterial Infections
Dashper, S. G., Nastri, A. L., & Abbott, P. V. (2019) · Springer eBooks · doi:10.1007/978-3-319-72303-7_45 · Cited by 8
Women and Bone Health: Maximizing the Benefits of Aromatase Inhibitor Therapy
Tang, S.-C. (2010) · Oncology · doi:10.1159/000314997 · Cited by 8
Osteonecrosis de los maxilares inducida por bifosfonatos: prevención y actitud terapéutica
Barrientos, F. J., Cagigal, B. P., Varela, G. D. L. P., Cuéllar, L. A. S., Cantera, J. M. G., Soto, A. S., & Hernández, A. V. (2007) · Revista Española de Cirugía Oral y Maxilofacial · doi:10.4321/s1130-05582007000500002 · Cited by 8
Metronomic administration of ibandronate and its anti-angiogenic effects in vitro
Morgan, C., Jeremiah, S., & Wagstaff, J. (2009) · Microvascular Research · doi:10.1016/j.mvr.2009.07.004 · Cited by 8
Basso, F. G., Turrioni, A. P. S., Hebling, J., & Costa, C. A. D. S. (2013) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2013.05.010 · Cited by 8
Sonthalia, N., Mukherjee, K., Saha, A., & Talukdar, A. (2012) · BMJ Case Reports · doi:10.1136/bcr-2012-006759 · Cited by 8
Lu, S.-Y., Liang, C.-C., & Lin, L.-H. (2013) · Journal of Dental Sciences · doi:10.1016/j.jds.2013.03.004 · Cited by 8
Liu, S., Lin, T., Fu, E., Hsia, Y., Chiu, H., Tu, H., & Chiang, C. (2019) · Journal of Periodontology · doi:10.1002/jper.18-0761 · Cited by 8
Hoesl, C. E., & Altwein, J. E. (2006) · Urologia Internationalis · doi:10.1159/000090869 · Cited by 8
Osteonecrosis of the Jaw and the Use of Antiangiogenic Agents: Just an Association?
Aragon‐Ching, J. B., & Dahut, W. L. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0206 · Cited by 8
Coleman, R. E. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.10.004 · Cited by 8
Ciobanu, G. A., Mogoantă, L., Popescu, S. M., Ionescu, M., Munteanu, C. M., Staicu, I. E., Mercuţ, R., Georgescu, C. C., Scrieciu, M., Vlad, D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814345 · Cited by 7
AFTIMOS, V. G., Zeinoun, T., Tayeh, R. B., & Aftimos, G. (2014) · International Journal of Dentistry · doi:10.1155/2014/869067 · Cited by 7
Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence
Daniele, G., Giordano, P., Luca, A. D., Piccirillo, M. C., Maïo, M. D., Giudice, A. D., Feo, G. D., Bryce, J., Lamura, L., Vecchione, A., et al. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.214 · Cited by 7
Hoddinott, K. L., Oblak, M. L., Wood, G. A., Boston, S. E., & Mutsaers, A. J. (2019) · Europe PMC (PubMed Central) · Cited by 7
Bisphosphonate Therapy in the Management of Symptomatic Melorheostosis of Tibia
Muthu, S., Chellamuthu, G., Chandrasekaran, S., & Gowtham, P. (2021) · Journal of Orthopaedic Case Reports · doi:10.13107/jocr.2021.v11.i09.2436 · Cited by 7
Prevention and Management of Osteonecrosis of the Jaw Associated with Bisphosphonate Therapy
Price, N., Lipton, A., Jain, V. K., & Ruggiero, S. L. (2004) · Supportive Cancer Therapy · doi:10.1016/s1543-2912(13)60101-0 · Cited by 7
Suyama, K., Noguchi, Y., Tanaka, T., Yoshida, T., Shibata, T., Saito, Y., & Tatsuno, I. (2007) · Oncology Reports · doi:10.3892/or.18.5.1291 · Cited by 7
Hughes, R., Chen, X., Hunter, K. D., Hobbs, J. K., Holen, I., & Brown, N. J. (2019) · The FASEB Journal · doi:10.1096/fj.201900553rr · Cited by 7
Bisphosphonates as a therapeutic choice for multifocal epithelioid hemangioma of bone
Tang, L., Chen, G., Wang, Q. L., Jobin, J., & Lu, C. (2019) · Medicine · doi:10.1097/md.0000000000018161 · Cited by 7
Toriumi, S., Shimokawa, K., Yamamoto, M., & Uesawa, Y. (2025) · Pharmaceuticals · doi:10.3390/ph18030423 · Cited by 6
Dietrich, E.-M., Theodora, P., Sioga, A., Georgios, K., & Esthelle, N. (2015) · Journal of Histology and Histopathology · doi:10.7243/2055-091x-2-24 · Cited by 6
Jain, V., Seith, A., Manchanda, S., Pillai, R. S., Sharma, D. N., & Mathur, V. P. (2019) · The Journal of Indian Prosthodontic Society · doi:10.4103/jips.jips_368_18 · Cited by 6
ÖZYURTSEVEN, B. T., Serin, İ., Nursal, A. F., Pehlıvan, S., & Pehlıvan, M. (2021) · BMC Oral Health · doi:10.1186/s12903-021-01634-9 · Cited by 6
Effects of ranibizumab and zoledronic acid on endometriosis in a rat model
Özdemir, E. Ü., Adalı, E., Taşkın, M. İ., Yavaşoğlu, A., Aktuğ, H., Oltulu, F., & Inceboz, U. S. (2021) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-021-06104-9 · Cited by 6
Current approaches for early detection and treatment of medication-related osteonecrosis of jaw
Janovszky, Á., Vereb, T., Szabó, A., & Piffkò, J. (2014) · Orvosi Hetilap · doi:10.1556/oh.2014.30046 · Cited by 6
Coelho, A. I., Gomes, P. D. S., & Fernandes, M. H. (2010) · Revista Portuguesa de Estomatologia Medicina Dentária e Cirurgia Maxilofacial · doi:10.1016/s1646-2890(10)70093-5 · Cited by 6
Sigamani, K. R., Vannala, V., Kumar, S. S., Reddy, B., Cherukuri, A., & Chandrasekhar, G. (2014) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.137440 · Cited by 6
Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells
Pietrovito, L., Comito, G., Parri, M., Giannoni, E., Chiarugi, P., & Taddei, M. L. (2019) · Current Cancer Drug Targets · doi:10.2174/1568009619666190115142858 · Cited by 6
Combinations of Bisphosphonates and Classical Anticancer Drugs: A Preclinical Perspective
Michailidou, M., & Holen, I. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-21892-7_7 · Cited by 6
Mandibular osteonecrosis due to bisphosphonate use
Şalvarcı, A., & Altınay, S. (2015) · Urology Research and Practice · doi:10.5152/tud.2015.90277 · Cited by 6
Inhibitors of Tumor Angiogenesis
Harris, A. L., & Generali, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00010-3 · Cited by 6
Wang, B., Yan, C., Lou, S., Emani, P. S., Li, B., Xu, M., Kong, X., Meyerson, W. U., Yang, Y., Lee, D., et al. (2019) · Structure · doi:10.1016/j.str.2019.06.001 · Cited by 6
Bisphosphonates and avascular necrosis of the mandible: Case report and review of the literature
Murray, D. J., Vesely, M. J. J., Novak, C. B., Irish, J., Crump, M., & Neligan, P. C. (2006) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2006.06.017 · Cited by 6
Osteonecrosis of the Jaw, a Recently Recognized Sequela of Bisphosphonate Therapy: Case Report
Langer, C. J. (2006) · Supportive Cancer Therapy · doi:10.3816/sct.2006.n.008 · Cited by 6
Denosumab and Atypical Femoral Fractures: A Scoping Literature Review
Ismail, A., Bekhet, A. H., Abushouk, A. I., Mirbaha, S., & Baratloo, A. (2017) · Trauma Monthly · doi:10.5812/traumamon.42869 · Cited by 6
Phosphore et bisphosphonates : ou quand on oublie les leçons du passé !
Carrel, J., Najm, S. A., Lysitsa, S. N., Lesclous, P., Lombardi, T., & Samson, J. (2006) · Médecine Buccale Chirurgie Buccale · doi:10.1051/mbcb/2006009 · Cited by 6
Osteonecrosis of the Jaw in a Patient Receiving Bisphosphonate Therapy
Reilly, M. M. (2007) · Oncology nursing forum · doi:10.1188/07.onf.301-305 · Cited by 6
Ostéonécrose des maxillaires dues aux bisphosphonates (2epartie) : expérience genevoise
Najm, S. A., Lesclous, P., Tommaso, L., Bouzouita, I., Carrel, J. P., & Samson, J. (2008) · Médecine Buccale Chirurgie Buccale · doi:10.1051/mbcb/2008019 · Cited by 5
Dental Care in the Patients with Bisphosphonates Therapy
Mishra, M. B., Mishra, S., & Mishra, R. (2011) · Cited by 5
Multiple Myeloma: The Role of Angiogenesis in Disease Progression
Ria, R. (2013) · Journal of Bone Marrow Research · doi:10.4172/2329-8820.1000117 · Cited by 5
Mohamed, M. M., Gunasekera, W., Glew, D., Bell, C., & Bhalla, A. K. (2022) · Clinical Medicine · doi:10.7861/clinmed.22-4-s20 · Cited by 5
The Biology of Bone Metastases from Prostate Cancer and the Role of Bisphosphonates
Clarke, N. W., & Fleisch, H. A. (2007) · Springer eBooks · doi:10.1007/978-1-4020-5847-9_12 · Cited by 5
Zhu, X., Amir, E., Singh, G., Clemons, M. J., & Addison, C. (2014) · Journal of bone oncology · doi:10.1016/j.jbo.2014.01.001 · Cited by 5
Pigrau, C., Cabral-Galeano, E., Almirante, B., Sordé, R., Rodríguez-Pardo, D., Fernández‐Hidalgo, N., Larrosa, N., Bescós, C., & Pahissa, A. (2013) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2013.01.007 · Cited by 5
Ide, H., Lü, Y., Kitamura, K., Muto, S., Yamaguchi, R., Tanaka, T., Wakumoto, Y., Masumori, N., & Horie, S. (2014) · Prostate International · doi:10.12954/pi.14056 · Cited by 5
Albu-Stan, I.-A., Petrovan, C., Cerghizan, D., Eremie, L. Y., Crăciun, A. E., & Copotoiu, C. (2018) · Journal of Interdisciplinary Medicine · doi:10.2478/jim-2018-0027 · Cited by 5
Cellular and molecular actions of bisphosphonates
Junankar, S. R., & Rogers, M. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00051-0 · Cited by 5
Impact of alendronate and VEGF-antisense combined treatment on highly VEGF-expressing A431 cells
Coulanges, M., Migianu‐Griffoni, E., Lecouvey, M., & Jollès, B. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.02.016 · Cited by 5
Pérez‐Sayáns, M., Real, C. V., Peñaranda, J. M. S., & Garcı́a, A. G. (2017) · InTech eBooks · doi:10.5772/intechopen.69315 · Cited by 5
Zoledronate alters natural progression of tissue‐engineered vascular grafts
Chang, Y., Li, J., Mirhaidari, G. J. M., Zbinden, J. C., Barker, J. C., Blum, K. M., Reinhardt, J. W., Best, C. A., Kelly, J. M., Shoji, T., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202001606rr · Cited by 5
Bisphosphonat-assoziierte Osteonekrosen des Kieferknochens
Krauth, M., Fügl, A., & Gruber, R. (2008) · Wiener klinische Wochenschrift · doi:10.1007/s00508-008-1002-9 · Cited by 5
Bisphosphonate-associated Osteonecrosis of the jaws and endodontic treatment: two case reports.
Goodell, G. G. (2006) · PubMed · Cited by 5
Khojasteh, A., Nazeman, P., & Rad, M. R. (2016) · Dental Hypotheses · doi:10.4103/2155-8213.183767 · Cited by 5
Jia, X., Cheng, J., Shen, Z., Shao, Z., & Liu, G. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8514 · Cited by 5
Nasulewicz‐Goldeman, A., Goldeman, W., Mrówczyńska, E., & Wietrzyk, J. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13597 · Cited by 5
Role of zoledronic acid in nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis
Sun, X.-S., Lin, C., Liang, Y.-J., Chen, Q.-Y., Tang, L., & Mai, H. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.08.003 · Cited by 5
Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer
Li, J., & Rugo, H. S. (2011) · Breast Disease · doi:10.3233/bd-2010-0326 · Cited by 5
Löwik, C. W. G. M., Cecchini, M. G., Maggi, A. C., & van der Pluijm, G. (2006) · Springer eBooks · doi:10.1007/3-540-26809-x_11 · Cited by 5
Budzinska, A., Gałgański, Ł., Wojcicki, K., & Jarmuszkiewicz, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-02710-8 · Cited by 4
Metadata
- Authors
- Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J. M., Castronovo, V., & Green, J. R.
- Affiliations
- Novartis (Switzerland) (CH)
- University of Liège (BE)
- ORCID
- Bellahcène, Akeila
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2002-01
- Volume
- 302
- Issue
- 3
- Pages
- 1055-1061
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2144860907
- Cited by
- 854
- References
- 33
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 14 · 2023: 20 · 2022: 17 · 2021: 18 · 2020: 22 · 2019: 34 · 2018: 23 · 2017: 20 · 2016: 24 · 2015: 38 · 2014: 46 · 2013: 44 · 2012: 36
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- zoledronic acid, bisphosphonates, antiangiogenic activity, angiogenesis inhibition, endothelial cell proliferation, basic fibroblast growth factor, vascular endothelial growth factor, endothelial cell adhesion, endothelial cell migration, tumor-induced osteolysis, malignant bone disease, chorioallantoic membrane assay
- MeSH terms
- Zoledronic Acid, Pamidronate, Cell Adhesion, Cell Cycle, Cell Movement, Cells, Cultured, Chemotaxis, Chorion, Diphosphonates, Endothelium, Vascular, Growth Substances, Humans, Imidazoles, Lymphokines, Muscle, Smooth, Vascular, Fibroblast Growth Factor 2, Endothelial Growth Factors, Apoptosis, Image Cytometry, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
